Factors associated with *Neisseria gonorrhoeae* azithromycin resistance in the Quebec sentinel network, 2015-2017

Karine Blouin Ph. D.^{1,2}, Fannie Defay M. Sc.¹, Sylvie Venne M.D., M. Sc.³, Brigitte Lefebvre Ph. D.⁴, Annick Trudelle M. Sc.¹ and Annie-Claude Labbé, M.D.⁵

Institut national de santé publique

Québec

¹Direction des risques biologiques et de la santé au travail; Institut national de santé publique du Québec (INSPQ),

2Département de médecine sociale et préventive, Université de Montréal;

³Direction de la prévention des ITSS, Ministère de la santé et des services sociaux du Québec; ⁴Laboratoire de santé publique du Québec, INSPQ; ⁵Département de microbiologie, infectiologie et immunologie, Université de Montréal; Québec, Canada.

Background

In Quebec, the rate of reported gonococcal infection has increased three-fold from 2011 to 2017 (23.4 to 72.9 per 100 000 persons), reaching 6 142 cases in 2017 (1). The emergence of *N. gonorrhoeae* azithromycin resistance (MIC \geq 2mg/L) has been very abrupt (2013 : 1,7%, 2014 : 6,7% , 2015 : 12,4%, 2016 : 19,9%, 2017 : 30,9%)(2). In response to this well-recognized public health issue, a sentinel network was established in the province in 2015.

The Quebec sentinel network for the surveillance of gonococcal infection, antibiotic resistance and treatment failures aims to:

- 1. Maintain a sufficient number of cultures for antimicrobial resistance surveillance;
- 2. Cross-link antimicrobial susceptibility data to epidemiological and clinical information;
- 3. Monitor treatment failures.

including all duplicates.

2016 for women/heterosexual men.

All participants

2017

2017

MSM

Objective

Examine associations between *N. gonorrhoeae* azithromycin resistance and epidemiological/clinical characteristics of cases in the Quebec sentinel network.

■ Between September 2015 and December 2017, 68% of episodes

■ Figure 1 shows azithromycin minimal inhibitory concentrations (MIC) of all strains. Higher values were observed for MSM compared to women/heterosexual men. There is a shift to the right in 2017 vs.

Figure 1

Azithromycin minimal inhibitory concentrations (MIC) by year, globally and stratified for MSM and heterosexual men/women

(for all strains, including duplicates), Quebec sentinel network, 2015-2017.

Darker colors indicate a higher proportion for a given MIC in a given year.

(840/1 240) had a culture performed and 571 strains were obtained,

Methods

Three regions participated in the sentinel network:

- **Montréal:** two clinics recruiting mostly men having sex with men (MSM);
- Montérégie: 22 clinics recruiting mostly heterosexuals;
- Nunavik: two health centers recruiting mainly heterosexual Inuit people (their participation ended in 2017).

Data collection started in September 2015. History and sex behaviors were collected through a self-administered questionnaire or by file review.

All *N. gonorrhoeae* strains isolated in clinical laboratories throughout the province of Quebec were submitted to the *Laboratoire de santé publique du Québec* (LSPQ) where antimicrobial susceptibility analyses were performed using the agar dilution method according to Clinical and Laboratory Standards Institute (3).

Statistical analyses:

One strain per clinical episode was selected (except for figure 1) prioritizing resistance first, then difficult to treat anatomical sites (pharynx>anus-rectum>urogenital site>other). The first episode per year, per individual was then selected, except otherwise stated. Proportion rates (PR) and 95% confidence intervals (95 % CI) were computed using generalized estimating equations (robust Poisson regression). Analyses were performed using SAS 9.4 and figure 1 was produced using R 3.5.3 and the ggplot2 package.

Results

Table 1

Proportion of azithromycin resistance (MIC ≥ 2 mg/L) according to sociodemographic information, sex behaviors and previous history of STBBIs, by year, Quebec sentinel network, 2015-2017

| Variables | | n: number of cases with azithromycin resistance/ N: number of strains tested within variable category | | | | | |
|---|--------------------------|---|------|----------|------|------------------------|------|
| | | 2016 | | 2017 | | 2015-2017 ³ | |
| | | n/N=190 | % | n/N=272 | % | n/N=470 | % |
| Sex ¹ | Men | 39 / 150 | 26.0 | 58 / 257 | 22.6 | 93 / 408 | 22.8 |
| | Women | 2 / 40 | 5.0 | 2 / 15 | 13.3 | 6 / 62 | 9.7 |
| Age (years) | < 25 | 13 / 48 | 27.1 | 9 / 46 | 19.6 | 20 / 100 | 20.0 |
| | 25-34 | 12 / 70 | 17.1 | 22 / 110 | 20.0 | 34 / 182 | 18.7 |
| | ≥ 35 | 16 / 72 | 22.2 | 29 / 116 | 25.0 | 45 / 188 | 23.9 |
| Region of residency | Montréal | 33 / 92 | 35.9 | 43 / 190 | 22.6 | 74 / 278 | 26.6 |
| | Outside Montréal | 8 / 98 | 8.2 | 17 / 82 | 20.7 | 25 / 192 | 13.0 |
| Sex partners (last year) among male cases | Heterosexual men | 1 / 21 | 4.8 | 3 / 21 | 14.3 | 4 / 49 | 8.2 |
| | MSM | 38 / 121 | 31.4 | 55 / 235 | 23.4 | 89 / 350 | 25.4 |
| Number of sex partners (previous two months) | 0-4 | 18 / 104 | 17.3 | 36 / 154 | 23.4 | 54 / 268 | 20.2 |
| | 5 or more | 10 / 31 | 32.3 | 11 / 76 | 14.5 | 20 / 104 | 19.2 |
| | Missing | 13 / 55 | 23.6 | 13 / 42 | 31.0 | 25 / 98 | 25.5 |
| Anatomical site | Urogenital | 23 / 127 | 18.1 | 42 / 190 | 22.1 | 63 / 329 | 19.2 |
| | Anus-rectum | 13 / 38 | 34.2 | 11 / 55 | 20.0 | 24 / 90 | 26.7 |
| | Pharynx | 5 / 25 | 20.0 | 7 / 27 | 25.9 | 12 / 51 | 23.5 |
| Previous gonorrhea | No | 15 / 84 | 17.9 | 11 / 82 | 13.4 | 26 / 175 | 14.9 |
| | Yes | 21 / 68 | 30.9 | 41 / 156 | 26.3 | 61 / 223 | 27.4 |
| | Missing | 5 / 38 | 13.2 | 8 / 34 | 23.5 | 12 / 72 | 16.7 |
| Previous STBBIs ² | No | 5 / 45 | 11.1 | 3 / 38 | 7.9 | 7 / 86 | 8.1 |
| | Yes, other than HIV | 25 / 95 | 26.3 | 39 / 177 | 22.0 | 67 / 279 | 24.0 |
| | Yes, HIV | 8 / 24 | 33.3 | 16 / 45 | 35.6 | 21 / 67 | 31.3 |
| | Missing | 3 / 26 | 11.5 | 2 / 12 | 16.7 | 4 / 38 | 10.5 |
| | Yes, other than syphilis | 22 / 82 | 26.8 | 37 / 163 | 22.7 | 60 / 251 | 23.9 |
| | Yes, syphilis | 11 / 37 | 29.7 | 18 / 59 | 30.5 | 28 95 | 29.5 |
| Sex with a partner usually residing outside Quebec (2 last months) | No | 16 / 96 | 16.7 | 28 / 131 | 21.4 | 43 / 236 | 18.2 |
| | Yes | 11 / 29 | 37.9 | 7 / 33 | 21.2 | 15 / 58 | 25.9 |
| | Missing | 14 / 65 | 21.5 | 25 / 108 | 23.2 | 41 / 176 | 23.3 |

- Cases of unknown sex and trans persons are excluded; ² STBBIs : sexually transmitted and blood-borne infections
- ³ When proportions were presented for the entire period 2015-2017, the most recent strain per individual was retained. For separate years, the first episode per year was retained.

Associations

.25 0.05 i 2 4 ; Azithromycin (MIC, mg/L)

Azithromycin (MIC, mq/L)

Azithromycin resistance was significantly associated with:

≤0.016 0.03 0.06 0.12 0.25 0.05 1 2 4 8 Azithromycin (MIC, mg/L)

≤0.016 0.03 0.06 0.12 0.25 0.05 1

≤0.016 0.03 0.06 0.12 0.25 0.05 1

Women and heterosexual men

- MSM vs. women and heterosexual men in 2016 (PR=6.39, 95 % CI [2.05-19.86], p<0.01), but not in 2017 (PR=1.69 [0.72-3.93], p=0.23)
- Reporting a sex partner outside Quebec in 2016 (PR=2.28, 95 % CI [1.19-4.34], p=0.01), but not in 2017 (PR=0.99, 95 % CI [0.48-2.07], p=0.98)
- Reporting previous sexually transmitted and blood-borne infections (STBBIs), globally in 2016 and 2017 (similar for both years)
 - o HIV vs. no STBBIs (PR=2.57, 95 % CI [1.25-5.27], p<0.01)
 - STBBIs other than HIV vs. no STBBIs) (PR=3.68, 95 % CI [1.71-7.91], p=0.01)

In multivariate analyses, azithromycin resistance remained significantly associated with MSM in 2016 and with previous STBBIs in 2016-2017 - adjusted for age, year, region of residency, anatomical site, number of sex partners and sex with a partner usually residing outside Quebec.

Conclusions

- Recommendations to perform cultures appear to be relatively well implemented (68% of episodes) but there is scope for improvement.
- Azithromycin resistance seems to be well established in Quebec, particularly but not exclusively in cases who reported previous STBBIs and in MSM.
 - Association between azithromycin resistance and MSM was observed in 2016 but not in 2017. This is consistent with the results of the surveillance program for all strains detected in Quebec, where the proportion of azithromycin resistance was higher in men than in women (21% vs.12%, p=0.003) in 2016, while in 2017, the observed proportions of azithromycin resistance were the same (30.9% in men and 31.2% in women).
- Acknowledgements

■ These results also suggest a possible declining contribution of trav-

■ The main limits include moderate sample size, high proportion

of missing information for some variables and sampling bias (i.e.

over-representation of MSM). Thus, these results would not be repre-

el-acquired resistant infection between 2016 and 2017.

This project is funded by the *Ministère de la santé et des services sociaux du Québec*.

Members of the steering committee and respondents from clinics/public health departments:

Clinics (clinique médicale l'Actuel, clinique médicale du Quartier Latin): Dr Danièle Longpré, Anne-Fanny Vassal, Hermione Gbego, Geneviève Guay, Mariève Beauchemin, Éric Lefebvre, Daria Khadir, Dr Émanuelle Huchet, Catherine Vigneault, Ioannis Vertzagias, Claude Vertzagias,

We thank all clinicians participating in the sentinel network for their excellent collaboration

Montréal public health: Dr Gilles Lambert

sentative of the entire province.

Montérégie: Dr Stéphane Roy, Andrée Perreault, Annick Bernatchez

Nunavik Dr Véronique Morin, Jade Équilbec, Faye LeGresley

For more information, please contact karine.blouin@inspq.qc.ca
Conflict of interest disclosure: The authors have no conflicts of interest.

References

- . Blouin K, Venne S. Lambert G. Portrait des infections transmissibles sexuellement et par le sang (ITSS) au Québec, Année 2017 et projections 2018. INSPQ. Institut national de santé publique du Québec. Décembre 2018.
- 2. Lefebvre, B, Labbé, A-C, Longtin, J. Sommaire des résultats d'antibiorésistance des souches de *Neisseria gonorrhoeae* au Québec : 2017. Institut national de santé publique du Québec. Octobre 2018. https://www.inspq.qc.ca/lspq/rapports-de-sur-
- veillance/sommaire-des-resultats-d-antibioresistance-des-souches-de-neisse-ria-gonorrhoeae-au-quebec-2017
- 3. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing. Twenty-seven informational supplement. CLSI document, approved standard M100–S27. Wayne (PA).